Association of increased Visfatin/PBEF/NAMPT circulating concentrations and gene expression levels in peripheral blood cells with lipid metabolism and fatty liver in human morbid obesity. Nutr. Metab. Cardiovasc. Dis. 25

Metabolic Research Laboratory, Clínica Universitaria de Navarra, University of Navarra, Pamplona, Spain.
Nutrition, metabolism, and cardiovascular diseases: NMCD (Impact Factor: 3.32). 04/2011; 21(4):245-53. DOI: 10.1016/j.numecd.2009.09.008
Source: PubMed


Nicotinamide phosphoribosyltransferase (NAMPT) is an adipokine with physiological effects on the control of glucose homeostasis as well as potentially involved in inflammation. The association of circulating NAMPT concentrations with obesity has not been clearly established. The aim of the present work was to evaluate the effect of obesity on circulating concentrations and gene expression levels of NAMPT in human peripheral blood cells (PBCs) as well as its involvement in inflammation, glucose and lipid metabolism.
Forty-four serum samples obtained from 14 lean and 30 obese volunteers were used to analyse the circulating concentrations of NAMPT. In addition, PBC, omental adipose tissue (OM) and liver biopsy samples obtained from a subgroup of subjects were used to determine transcript levels of NAMPT by Real-time PCR. Glucose and lipid profile as well as several inflammatory factors and hepatic enzymes were analysed. NAMPT circulating concentrations (P<0.01) and gene expression levels in PBC (P<0.05) were significantly increased in obese patients as compared to lean subjects. Total-cholesterol (P=0.016), HDL-cholesterol (P=0.036) and triglycerides (P=0.050) were significant and independent determinants of circulating concentrations of NAMPT (P<0.01). Moreover, a positive correlation (P<0.01) was found with the hepatic enzymes alanine aminotransferase, aspartate aminotransferase, and γ-glutamyltransferase after BMI adjustment.
Our work shows that NAMPT circulating concentrations and mRNA expression levels in PBC are increased in obese patients and that plasma NAMPT levels are related to inflammation, lipid metabolism and hepatic enzymes suggesting a potential involvement in fatty liver disease and in the obesity-associated inflammatory state.

Download full-text


Available from: Amaia Rodríguez, Dec 17, 2013
  • Source
    • "Excessive fat accumulation is associated with increased expression of cytokines related to inflammation and immune response in both adipose tissue [2] and white blood cells (WBC) [3] [4]. Recent studies have identified the role of adipokines, such as leptin, resistin, and visfatin on the variation of gene expression in WBC, indicating the relationship between adipose tissue status and WBC functions [5] [6]. On the other hand, some dietary components (e.g. "
    [Show abstract] [Hide abstract]
    ABSTRACT: The aim of this article is to assess the potential relationships between TNFα gene promoter methylation in peripheral white blood cells and central adiposity (truncal fat), metabolic features and dietary fat intake. A group of 40 normal-weight young women (21±3y; BMI 21.0±1.7kg/m(2)) was included in this cross-sectional study. Anthropometric, biochemical and dietary data were assessed using validated procedures. DNA from white blood cells was isolated and 5-methylcytosine levels of the CpGs sites present in TNFα gene promoter (from -170 to +359 pb) were analyzed by Sequenom EpiTyper. Those women with high truncal fat (⩾52.3%) showed lower 5-methylcytosine levels (P<0.05) in the site CpG13 (at position +207) and CpG19 (+317 pb) of the TNFα gene promoter when were compared to women with lower truncal adiposity. The methylation levels of CpG13 were also correlated with circulating TNFα levels, which were higher in those women with greater truncal adiposity. In a linear regression model, truncal fat, HDL-cholesterol, insulin, plasma TNFα, and daily n-6 PUFA intake explained the methylation levels of CpG13 site +207 by 48% and the average of CpG13 and CpG19 by 43% (P<0.001). In conclusion, women with higher truncal fat showed lower methylation levels of TNFα promoter in peripheral white blood cells and higher plasma TNFα concentrations. DNA methylation levels of TNFα promoter were associated with some metabolic features and with n-6 PUFA intake, suggesting a complex nutriepigenomic network in the regulation of this recognized pro-inflammatory marker.
    Cytokine 06/2013; 64(1). DOI:10.1016/j.cyto.2013.05.028 · 2.66 Impact Factor
  • Source
    • "Previous studies have shown that changes in adipokine level affect cell proliferation, apoptosis, invasion, and angiogenesis in the progression of breast cancer (Percik and Stumvoll, 2009; Vona-Davis and Rose, 2007). Visfatin is a newly found candidate for an obesity-induced adipokine involved in the cancer progression, because serum visfatin level is greatly increased in parallel with increase of fat accumulation and obesity (Catalán et al., 2010; Fukuhara et al., 2005), and because it has been well known to be involved in the proliferation of early B cell lines (as PBEF) (Samal et al., 1994) and in the cellular energy metabolism (as Nampt) (Imai, 2009). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Obesity, a condition characterized by increased fat content and altered secretion of adipokines, is a risk factor for postmenopausal breast cancer. Visfatin has recently been established as a novel adipokine that is highly enriched in visceral fat. Here we report that visfatin regulated proliferation of MCF-7 human breast cancer cells. Exogenous administration of recombinant visfatin increased cell proliferation and DNA synthesis rate in MCF-7 cells. Furthermore, visfatin activated G1-S phase cell cycle progression by upregulation of cyclin D1 and cdk2 expression. Visfatin also increased the expression of matrix metalloproteinases 2, matrix metalloproteinases 9, and vascular endothelial growth factor genes, suggesting that it may function in metastasis and angiogenesis of breast cancer. Taken together, these findings suggest that visfatin plays an important role in breast cancer progression.
    Moleculer Cells 10/2010; 30(4):341-345. DOI:10.1007/s10059-010-0124-x · 2.09 Impact Factor
  • Source
    • "Several studies have shown that there are different disorders that exhibit altered plasma levels of this protein [153–156]. Thus, visfatin plasma concentrations may potentially be related to lipid metabolism [157] and the inflammatory response [158]. Since an increased expression of this protein has been observed in the macrophages of unstable carotid and coronary atherosclerosis in humans [159], and there is a negative association between the visfatin plasma levels of visfatin and vascular endothelial function [160], it has been proposed that visfatin plays a role in plaque destabilization. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Obesity, the most common nutritional disorder in industrialized countries, is associated with an increased mortality and morbidity of cardiovascular disease (CVD). Obesity is primarily considered to be a disorder of energy balance, and it has recently been suggested that some forms of obesity are associated with chronic low-grade inflammation. The present paper focuses on the current status of our knowledge regarding chronic inflammation, a link between obesity and CVDs, including heart diseases, vascular disease and atherosclerosis. The paper discusses the methods of body fat evaluation in humans, the endocrinology and distribution of adipose tissue in the genders, the pathophysiology of obesity, the relationship among obesity, inflammation, and CVD, and the adipose tissue-derived cytokines known to affect inflammation. Due to space limitations, this paper focuses on C-reactive protein, serum amyloid A, leptin, adiponectin, resistin, visfatin, chemerin, omentin, vaspin, apelin, and retinol binding protein 4 as adipokines.
    Mediators of Inflammation 08/2010; 2010(7):535918. DOI:10.1155/2010/535918 · 3.24 Impact Factor
Show more